Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31642200 | 1.00 | FOLH1 (0.54) | FOLH1GSRSLC6A5CPB2RNPEP | |
| SCHEMBL168589 | 0.98 | FOLH1 (0.56) | FOLH1GSRSLC6A5CPB2RNPEP | |
| SCHEMBL164121 | 0.98 | FOLH1 (0.56) | FOLH1GSRSLC6A5CPB2RNPEP | |
| SCHEMBL165084 | 0.98 | FOLH1 (0.56) | FOLH1GSRSLC6A5CPB2RNPEP | |
| Hydrochloric Acid SCHEMBL25283310 | 0.96 | FOLH1 (0.54) | FOLH1GSRSLC6A5CPB2RNPEP | |
| Methane SCHEMBL15135721 | 0.96 | FOLH1 (0.54) | FOLH1GSRSLC6A5CPB2RNPEP | |
| Methane SCHEMBL15135720 | 0.96 | FOLH1 (0.54) | FOLH1GSRSLC6A5CPB2RNPEP | |
| Hydrochloric Acid SCHEMBL2844807 | 0.96 | FOLH1 (0.54) | FOLH1GSRSLC6A5CPB2RNPEP | |
| Hydrochloric Acid SCHEMBL8332033 | 0.96 | FOLH1 (0.54) | FOLH1GSRSLC6A5CPB2RNPEP | |
| Bromide SCHEMBL6933931 | 0.96 | FOLH1 (0.54) | FOLH1GSRSLC6A5CPB2RNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | claimed |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | RAYZEBIO, INC. (US) | 2025-07-10 | — | — | US | claimed |
| WO-2025137441-A1 | RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4720087-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2026-04-08 | — | — | EP | disclosed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | RAYZEBIO, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| WO-2025137443-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025137441-A1 | RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2024246269-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | ZEALAND PHARMA A/S (DK) | 2024-12-05 | — | — | WO | disclosed |
| CN-118401257-A | Methods for producing antibody peptide conjugates | 美国安进公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-110831969-B | Methods of treating or ameliorating metabolic disorders using a combination of a Gastric Inhibitory Peptide Receptor (GIPR) binding protein and a GLP-1 agonist | 安进公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-118079021-A | Treatment or amelioration of metabolic disorders using GLP-1 receptor agonists coupled to Gastric Inhibitory Peptide Receptor (GIPR) antagonists | 美国安进公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-110662558-B | Treatment or amelioration of metabolic disorders using GLP-1 receptor agonists coupled to Gastric Inhibitory Peptide Receptor (GIPR) antagonists | 美国安进公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117106085-A | Methods of treating or ameliorating metabolic disorders using combinations of GIPR binding proteins and GLP-1 agonists | 美国安进公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-110621695-B | anti-JAGGED 1 antigen binding proteins | 安进公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-109715662-B | Methods of treating or ameliorating metabolic disorders using combinations of GIPR binding proteins and GLP-1 agonists | 美国安进公司 | 2023-07-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | FOLH1 239/4885GSR 4755/4885SLC6A5 1165/4885 |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | SSTR2, SSTR4, SSTR5 | FOLH1 19/4885GSR 2461/4885SLC6A5 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.